Neurocrine Biosciences Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Neurocrine Biosciences Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: SAN Diego
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: NBIX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000914475
EIN: 33-0525145
Wikidata ID: Q7002174

Board of directors

Follow this board

Christine A. Poon · Director
Since 2023
Gary A. Lyons · Director
Since 2023
George J. Morrow · Director
Since 2023
Johanna Mercier · Director
Since 2023
Kevin Charles Gorman · Director · Chief Executive Officer
Since 2023
Kyle Gano · Director · Chief Executive Officer
Since 2024
Leslie Norwalk V · Director
Since 2023
Richard F. Pops · Director
Since 2023
Shalini Sharp · Director Overboarded
Since 2023
Stephen A. Sherwin · Director
Since 2023
William H. Rastetter · Director
Since 2023

Chief executives

Kevin Charles Gorman · Chief Executive Officer

Dates unknown

Kyle Gano · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of May 21, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 20 other boards. 17 are in the same sector.

Shared director Other board Same sector +4 more in the list below

Iambic Therapeutics Inc. Same sector
via Shalini Sharp and William H. Rastetter
Align Technology Inc. Same sector
via George J. Morrow
Alkermes plc Same sector
via Richard F. Pops
Arcus Biosciences Inc. Same sector
via Johanna Mercier
Arvinas Inc. Same sector
via Leslie Norwalk V
BeOne Medicines Ltd. Same sector
via Shalini Sharp
Biogen Inc. Same sector
via Stephen A. Sherwin
CVS Health Corporation
via Leslie Norwalk V
Dare Bioscience Inc. Same sector
via William H. Rastetter
Eledon Pharmaceuticals Inc. Same sector
via Gary A. Lyons
Fate Therapeutics Inc. Same sector
via William H. Rastetter
Globus Medical Inc. Same sector
via Leslie Norwalk V
Organon & Co. Same sector
via Shalini Sharp
Prudential Financial Inc.
via Christine A. Poon
Regeneron Pharmaceuticals Inc. Same sector
via Christine A. Poon
Rigel Pharmaceuticals Inc. Same sector
via Gary A. Lyons
Septerna Inc. Same sector
via Shalini Sharp
The Sherwin-Williams Company
via Christine A. Poon
Travere Therapeutics Inc. Same sector
via Gary A. Lyons
Xencor Inc. Same sector
via Kevin Charles Gorman

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $77,431,384; 50 sales by 14 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 3, 2026	George J. Morrow Director	Option exercise	+7,200	$53.64	$386,208
Nov 3, 2026	George J. Morrow Director	Open-market sale	−100	$158.18	$15,818
Nov 3, 2026	George J. Morrow Director	Open-market sale	−100	$162.05	$16,205
Nov 3, 2026	George J. Morrow Director	Open-market sale	−600	$163.71	$98,225
Nov 3, 2026	George J. Morrow Director	Open-market sale	−1,226	$164.74	$201,971
Nov 3, 2026	George J. Morrow Director	Open-market sale	−908	$165.71	$150,461
Nov 3, 2026	George J. Morrow Director	Open-market sale	−1,466	$166.77	$244,492
Nov 3, 2026	George J. Morrow Director	Open-market sale	−1,500	$167.72	$251,587
Nov 3, 2026	George J. Morrow Director	Open-market sale	−1,300	$168.53	$219,092
Nov 2, 2026	George J. Morrow Director	Option exercise	+7,500	$53.64	$402,300
Nov 2, 2026	George J. Morrow Director	Open-market sale	−1,900	$144.98	$275,453
Nov 2, 2026	George J. Morrow Director	Open-market sale	−4,300	$145.86	$627,194
Nov 2, 2026	George J. Morrow Director	Open-market sale	−1,300	$146.76	$190,783
Nov 1, 2026	Kyle Gano Director, Officer (Chief Executive Officer)	Option exercise	+614	—	—
Nov 1, 2026	Kyle Gano Director, Officer (Chief Executive Officer)	Shares withheld for tax	−332	$146.10	$48,505

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Neurocrine Biosciences Inc.

Who is the CEO of Neurocrine Biosciences Inc.?

Kevin Charles Gorman is Neurocrine Biosciences Inc.'s Chief Executive Officer.

How many directors are on Neurocrine Biosciences Inc.'s board?

Neurocrine Biosciences Inc.'s board has 11 directors: Christine A. Poon, Gary A. Lyons, George J. Morrow, Johanna Mercier, Kevin Charles Gorman, Kyle Gano, Leslie Norwalk V, Richard F. Pops, Shalini Sharp, Stephen A. Sherwin and 1 other.

Are Neurocrine Biosciences Inc. insiders buying or selling shares?

Over the last 12 months, Neurocrine Biosciences Inc. insiders made no open-market purchases and sold $77.4 million of shares in 50 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Neurocrine Biosciences Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="neurocrine-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.